Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
The cream has an estimated market size of US $ 28 million for twelve months ending Jun 2021 according to IQVIA
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
The centre has an initial capacity of 500 FTEs
Subscribe To Our Newsletter & Stay Updated
